Small Humanin-Like Peptides (SHLPs 1–6): Complete Research Profile — Mitochondrial Microproteins Governing Cellular Survival, Metabolic Homeostasis, and Neurodegeneration (2026)

What Are Small Humanin-Like Peptides?

Small humanin-like peptides (SHLPs) are a family of six mitochondrial microproteins — designated SHLP1 through SHLP6 — encoded within the 16S ribosomal RNA (rRNA) gene of the mitochondrial genome. Discovered in 2016 by Brendan Kimura, Su-Jeong Kim, and colleagues in Pinchas Cohen's laboratory at the University of Southern California Leonard Davis School of Gerontology, SHLPs represent a significant expansion of the mitochondria-derived peptide (MDP) class of bioactive molecules first exemplified by humanin.

Like humanin and the more recently characterized MOTS-c, SHLPs are translated from small open reading frames (sORFs) embedded within mitochondrial ribosomal RNA sequences — genomic regions long thought to be non-coding. Their discovery upended the prevailing view that the mitochondrial genome produces only 13 protein-coding gene products, revealing instead that mitochondria harbor an expanded peptidome with broad regulatory functions.

Each of the six SHLPs is between 20 and 38 amino acids in length and displays distinct tissue expression patterns, receptor interactions, and biological activities. Collectively, the SHLP family regulates apoptosis, mitochondrial biogenesis, oxidative stress responses, metabolic homeostasis, and inflammatory signaling — with each member occupying a unique niche within this regulatory landscape.

> Research Use Only (RUO): All content on this page describes SHLPs strictly for laboratory research purposes. SHLPs are not approved for human or veterinary therapeutic use. No claims regarding clinical outcomes, medical treatments, or human health applications are made or implied.

---

Discovery and Genomic Architecture

Mitochondrial DNA and the 16S rRNA Locus

The human mitochondrial genome is a circular double-stranded DNA molecule of approximately 16,569 base pairs. It encodes 13 polypeptides (all subunits of the oxidative phosphorylation complexes), 22 transfer RNAs, and 2 ribosomal RNAs: the 12S rRNA and the 16S rRNA. The 16S rRNA gene spans roughly 1,571 base pairs and was, until recently, considered a purely structural component of the mitoribosome.

An in silico analysis of mitochondrial 16S rRNA sequences identified multiple short open reading frames (sORFs) with the potential to encode small peptides. The original SHLP discovery paper by Kimura et al. (2016), published in Aging, confirmed that six of these sORFs are actively translated under physiological conditions and produce peptides with measurable biological activities in mammalian cells — including pancreatic β-cells (NIT-1) and prostate cancer cells (22Rv1).

Relationship to Humanin

Humanin itself is encoded in a complementary sORF within the 16S rRNA region. The SHLP designation reflects their structural and genomic proximity to humanin. All seven peptides (humanin + SHLP1–6) originate from the same ~1.5 kb genomic locus, yet differ markedly in sequence, structure, and downstream signaling. This gene clustering suggests a coordinated regulatory program in which the mitochondrial genome communicates with the cytoplasm and nucleus across multiple signaling axes.

---

SHLP Family Overview: Sequences and Tissue Distribution

All six SHLPs are relatively short peptides, but each has a unique amino acid composition and tissue-specific expression profile. Based on original characterization and subsequent studies, the expression landscape is as follows:

SHLP2's canonical 26-amino-acid sequence is: MGVKFFTLSTRFFPSVQRAVPLWTNS. This sequence contains a hydrophobic core that is thought to facilitate membrane interactions critical to its receptor binding and mitochondrial membrane potential effects.

---

SHLP2: The Most Studied Mitochondrial Microprotein

SHLP2 has emerged as the most extensively studied member of the SHLP family, with research published across aging, neuroscience, metabolic disease, and ophthalmology.

Anti-Apoptotic and Mitochondrial Protective Effects

The foundational 2016 Kimura et al. study established SHLP2 and SHLP3 as potent inhibitors of apoptosis in multiple cell types. Treatment with exogenous SHLP2 enhances cell viability under cytotoxic stress, reduces caspase activation, promotes mitochondrial biogenesis, decreases reactive oxygen species (ROS) generation, and protects mitochondrial DNA from oxidative damage.

Unlike many cytoprotective agents that act downstream of commitment to apoptosis, SHLP2 appears to modulate upstream mitochondrial health parameters — particularly membrane potential maintenance and complex protein expression in the electron transport chain. This upstream action may explain its broad protective profile across diverse cell types.

Metabolic Regulation via Hypothalamic Signaling

A landmark 2023 study in Nature Communications by Lee et al. demonstrated that SHLP2 plays an unexpected role in systemic energy homeostasis through central nervous system actions. Both systemic and intracerebroventricular (icv) administration of SHLP2 protected male mice from high-fat diet-induced obesity and improved insulin sensitivity. Mechanistically, SHLP2 was found to activate pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus, suppressing food intake and promoting thermogenesis in brown adipose tissue.

Crucially, the researchers identified CXCR7 (ACKR3) — an atypical chemokine receptor — as the primary binding partner of SHLP2. SHLP2 induces β-arrestin recruitment to CXCR7 with an EC50 of approximately 0.97 µM and promotes receptor internalization, classifying it as a biased CXCR7 agonist. This discovery links mitochondrial-derived signaling directly to hypothalamic melanocortin circuitry, a key axis in metabolic homeostasis.

These findings are significant for obesity and type 2 diabetes research, where central and peripheral insulin sensitization remain major unmet targets.

Neuroprotection: Parkinson's Disease

SHLP2 has attracted substantial attention as a neuroprotective factor. A 2024 study published in Molecular Psychiatry by Miller et al. identified a naturally occurring mitochondrial DNA single-nucleotide polymorphism (mtSNP: m.2158 T>C) that changes lysine 4 to arginine in the SHLP2 sequence — producing the K4R variant. Individuals carrying this variant showed approximately 50% reduced risk of Parkinson's disease in a large-scale population genetics analysis.

In mechanistic in vitro studies, the K4R variant more potently inhibited neurotoxin-induced apoptosis in dopaminergic neurons, reversed mitochondrial membrane potential loss, and restored mitochondrial respiration defects compared to wild-type SHLP2. These findings suggest that SHLP2 is not merely a correlate of mitochondrial health but a causal genetic determinant of neurodegeneration risk — with the K4R substitution conferring a gain-of-neuroprotective-function.

This represents one of the few mitochondrially-encoded genetic variants with validated protection against a major neurodegenerative disease.

Ocular Research: Age-Related Macular Degeneration

Gong et al. (2018) in Scientific Reports characterized SHLP2's protective effects in the context of age-related macular degeneration (AMD), a leading cause of irreversible vision loss worldwide. In AMD transmitochondrial cybrid cells — cell lines harboring AMD patient-derived mitochondria — SHLP2 treatment restored electron transport chain complex protein subunits required for oxidative phosphorylation (OXPHOS).

SHLP2 was further characterized as a molecular chaperone capable of binding islet amyloid polypeptide (IAPP) and blocking amyloid seeding, a process implicated in both AMD pathology and type 2 diabetes. It also reduced amyloid-β toxicity in retinal pigment epithelial cells — connecting its activity to the broader amyloid aggregation research domain.

The convergence of anti-apoptotic, anti-amyloid, and OXPHOS-restoring activities in a single 26-amino-acid peptide makes SHLP2 an unusually multifunctional research molecule.

---

SHLP3: Adipogenesis, ERK Signaling, and Insulin Sensitivity

SHLP3 shares the anti-apoptotic and cytoprotective properties of SHLP2, but adds a distinct metabolic dimension related to adipose tissue biology. In the Kimura et al. (2016) characterization study, SHLP3 was shown to promote adipocyte differentiation and activate ERK (extracellular signal-regulated kinase) signaling in mesenchymal precursor cells.

SHLP3's pro-adipogenic effect — while seemingly paradoxical in the context of metabolic disease research — likely reflects a role in healthy adipose tissue development and lipid partitioning. Hyperinsulinemic-euglycemic clamp studies demonstrated that centrally administered SHLP3 can enhance peripheral glucose uptake, positioning it alongside SHLP2 as a potential insulin-sensitizing factor.

SHLP3 is predominantly expressed in the brain and spleen, suggesting particular relevance to neuroimmune crosstalk — an emerging area where mitochondrial function and immune regulation intersect.

---

SHLP6: The Pro-Apoptotic Outlier with Anti-Tumor Implications

SHLP6 diverges sharply from the cytoprotective profile of SHLP2 and SHLP3. Rather than inhibiting apoptosis, SHLP6 induces it — significantly increasing programmed cell death in both pancreatic β-cells (NIT-1) and prostate cancer cells (22Rv1). This makes SHLP6 a compelling candidate for research into selective cancer cell cytotoxicity, where targeted induction of apoptosis in malignant but not healthy cells is a primary objective.

A 2023 study in Scientific Reports by Thangaraj et al. examined evolutionary conservation across the SHLP family and found that humanin and SHLP6 specifically showed strong synonymous codon bias and substantial sequence conservation across mammalian lineages — suggesting both are subject to purifying natural selection. This evolutionary constraint implies that SHLP6's pro-apoptotic function is not an aberrant byproduct but a conserved biological role — potentially as a quality-control mechanism for eliminating damaged or hyperproliferative cells.

By contrast, SHLP1, SHLP2, SHLP3, and SHLP5 showed minimal conservation, indicating they may be more recently evolved or positively selected for functional diversification.

---

Age-Dependent Decline: SHLPs as Biomarkers of Mitochondrial Aging

One of the most compelling aspects of SHLP biology from an aging research standpoint is that circulating SHLP levels change with age. The Kimura et al. (2016) study demonstrated that plasma SHLP2 concentrations decline with age in both mice and humans, mirroring the age-dependent decline previously documented for humanin.

This age-associated reduction in cytoprotective MDPs has led to the "mitokine decline" hypothesis — the proposal that aging-related loss of mitochondrial microprotein signaling contributes to increased cellular vulnerability to apoptotic insults, metabolic dysregulation, and neurodegeneration. Under this model, declining SHLP2 and humanin levels in aged individuals reflect the progressive failure of mitochondria to mount adequate cytoprotective responses.

Conversely, conditions associated with accelerated aging — including type 2 diabetes, Alzheimer's disease, and cardiovascular disease — are associated with lower circulating MDP levels, raising the possibility that SHLP2 or humanin might serve as circulating biomarkers of biological versus chronological aging in research settings.

---

SHLP Research in the Context of the Broader MDP Family

SHLPs exist alongside other established mitochondrial-derived peptides, most notably:

• •Humanin — The founding MDP; anti-apoptotic, cytoprotective, declines with age and in Alzheimer's disease
• •MOTS-c — Acts primarily as an exercise-mimetic metabolic regulator; translocates to the nucleus under stress
• •SHLPs 1–6 — Structural relatives of humanin with distinct and partially opposing activities

Within this framework, SHLP2 and humanin share overlapping anti-apoptotic activities, MOTS-c and SHLP2 share metabolic regulatory functions, and SHLP6 uniquely provides pro-apoptotic activity within the family — suggesting the mitochondrial 16S rRNA locus encodes a sophisticated, internally balanced regulatory system that can both promote and suppress cell survival depending on physiological context.

Why Study SHLPs Specifically?

Several features distinguish SHLP research from the broader humanin/MOTS-c literature:

1. Functional diversity within a single genomic locus — the SHLP1–6 family encompasses opposing biological activities (cytoprotective vs. pro-apoptotic) from closely clustered sORFs, providing a natural model for studying how small regulatory peptides achieve functional specificity.

2. CXCR7 receptor biology — SHLP2's identification as a CXCR7 agonist connects mitochondrial peptide biology to the chemokine receptor field, opening new avenues for understanding atypical GPCR signaling.

3. Genetic epidemiology — The K4R SHLP2 variant's association with halved Parkinson's risk represents one of the strongest mtDNA-encoded protective effects identified in neurodegenerative disease genetics.

4. Evolutionary selection — The differential conservation of SHLP6 versus other family members provides a window into the evolutionary pressures shaping mitochondrial genome content.

---

Research Applications and Study Design Considerations

For investigators incorporating SHLPs into research models, several methodological considerations apply:

Peptide synthesis and stability: SHLPs are relatively short peptides amenable to solid-phase peptide synthesis (SPPS). SHLP2's hydrophobic core may require careful handling and solubilization strategies to prevent aggregation. Reconstitution in DMSO with subsequent aqueous dilution is a common approach.

Dose-response characterization: The CXCR7 EC50 of SHLP2 (~1 µM in β-arrestin assays) provides a starting point for receptor engagement studies, but cellular functional assays (e.g., POMC neuron activation, mitochondrial membrane potential) may reflect different effective concentration ranges.

Age-matched controls: Given the age-dependent decline in circulating SHLP2, age-matched experimental groups are critical for in vivo metabolic and neuroprotection studies to avoid confounding by endogenous SHLP level differences.

Cell model selection: The opposing activities of SHLP2 (cytoprotective) and SHLP6 (pro-apoptotic) in the same NIT-1 and 22Rv1 cell lines underscore the importance of selecting appropriate cell models and interpreting results in the context of the full SHLP family.

Detection and quantification: SHLP2 circulating levels can be measured by ELISA in plasma or serum. Researchers should note that SHLP5-specific antibodies have historically been difficult to produce due to sequence features, limiting direct study of this family member.

---

SHLP2 and the K4R Genetic Variant: Implications for Mitochondrial Genetics Research

The identification of the m.2158 T>C mtSNP — encoding the K4R substitution in SHLP2 — has several implications for mitochondrial genetics research:

1. Heteroplasmy considerations: Mitochondrial DNA variants exist in a state of heteroplasmy (mixtures of variant and wild-type genomes within a cell). The K4R variant's protective effect likely depends on heteroplasmy level, adding complexity to population genetics interpretations.

2. Haplogroup stratification: The frequency of m.2158 T>C varies across mtDNA haplogroups, which have distinct geographic distributions. This haplogroup dependence may contribute to population-level differences in Parkinson's disease prevalence that have been difficult to explain through nuclear genome variation alone.

3. Functional rescue experiments: The K4R variant provides a naturally occurring gain-of-function tool for mechanistic studies of SHLP2's neuroprotective pathway in iPSC-derived dopaminergic neurons and other relevant neuronal cell models.

---

Current Research Frontiers

The SHLP field, while growing rapidly, remains in relatively early stages compared to more established MDP research programs. Key open questions include:

• •Receptor biology for SHLP3, 4, 5, and 6: SHLP2's CXCR7 interaction is established, but cognate receptors for other SHLPs remain incompletely characterized.
• •SHLP secretion and cell-to-cell communication: Whether SHLPs function as autocrine/paracrine signals from mitochondria-rich tissues (e.g., muscle, liver) to peripheral organs or the CNS is under active investigation.
• •SHLP6 cancer biology: SHLP6's conserved pro-apoptotic activity makes it an emerging area of interest for oncology research, particularly in tumor types reliant on mitochondrial metabolism.
• •Combined MDP signaling networks: How humanin, MOTS-c, and SHLPs interact and potentially synergize — whether they form a coordinated mitochondrial peptide communication system — remains an open and experimentally tractable question.

---

Key Research Citations

1. Kimura B, Kim SJ, et al. "Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers." Aging. 2016;8(4):796–809. PMID: 27070352

2. Miller B, et al. "A naturally occurring variant of SHLP2 is a protective factor in Parkinson's disease." Molecular Psychiatry. 2024;29(5):1297–1306. PMID: 38167865 DOI: 10.1038/s41380-023-02344-0

3. Lee C, et al. "Mitochondria-derived peptide SHLP2 regulates energy homeostasis through the activation of hypothalamic neurons." Nature Communications. 2023;14:4515. DOI: 10.1038/s41467-023-40082-7

4. Gong Z, et al. "Characterizing the protective effects of SHLP2, a mitochondrial-derived peptide, in macular degeneration." Scientific Reports. 2018;8:1–11. DOI: 10.1038/s41598-018-33290-5

5. Thangaraj MP, et al. "Evidence of natural selection in the mitochondrial-derived peptides humanin and SHLP6." Scientific Reports. 2023;13:14430. PMID: 37644144

6. Lee C, et al. "Mitochondria-derived peptides in aging and healthspan." Journal of Clinical Investigation. 2022;132(11):e158449. DOI: 10.1172/JCI158449